Patients treated with IgM-IVIg had a significantly lower body mass index (BMI) with a median of 26.5 vs. 31.8 (p = 0.015) and suffered more often from diabetes (p = 0.03) and renal insufficiency prior to admission to the ICU (p = 0.019). This evidence concerns the gene CD40LG and Renal insufficiency.